SciSparc Ltd
Company Profile
Business description
SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company’s operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
Contact
20 Raul Wallenberg Street
Tower A, 2nd Floor
Tel Aviv6971916
ISRT: +972 37175777
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
2
Stocks News & Analysis
stocks
Looking for growth outside the ASX100
stocks
Netflix and Warner Bros. Discovery: Surprisingly high merger price alters shareholder value for both
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,915.00 | 26.10 | 0.29% |
| CAC 40 | 8,091.62 | 23.12 | -0.28% |
| DAX 40 | 24,087.47 | 59.33 | 0.25% |
| Dow JONES (US) | 47,954.99 | 104.05 | 0.22% |
| FTSE 100 | 9,652.77 | 14.24 | -0.15% |
| HKSE | 25,765.36 | 319.72 | -1.23% |
| NASDAQ | 23,578.13 | 72.99 | 0.31% |
| Nikkei 225 | 50,581.94 | 90.07 | 0.18% |
| NZX 50 Index | 13,486.32 | 2.33 | 0.02% |
| S&P 500 | 6,870.40 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,624.40 | 28.80 | 0.34% |
| SSE Composite Index | 3,924.08 | 21.27 | 0.55% |